Effects of hydrogen-rich water on hamsters with experimental myeloid tumor
Toshkova R, Neshev N, Ignatov I, Huether F, Ignatov AI, Angushev I. · Libri Oncologici. 2023;51(2-3):85–96.
What kind of evidence is this?
Preclinical
Controlled hamster tumor study with survival and laboratory analyses
Cancer research
H₂-rich water
Not reported in this record.
Not reported in this record.
Methods at a glance
Golden Syrian hamsters with a subcutaneous experimental myeloid tumor plus a small healthy reference group.
19 hamsters: tumor plus hydrogen-rich water n=8, tumor plus deionized water n=8, and healthy deionized-water controls n=3. Three animals per group were selected on day 25 for blood analyses, leaving five per tumor group for growth and survival follow-up.
5-day pretreatment plus 25 days after tumor inoculation; survival followed until all tumor-bearing animals died.
Hydrogen-rich water was available ad libitum from 5 days before subcutaneous inoculation of 2×10⁴ viable tumor cells through 25 days afterward; fresh water was prepared daily.
H₂ dissolved in drinking water — H₂ only, not Brown's gas.
1.2 ppm dissolved H₂; pH 7.3; oxidation-reduction potential reported between -405 and -390 mV. Actual water consumption per animal was not reported.
Not applicable — drinking water, not gas inhalation.
No O₂ was co-delivered as part of the intervention.
Tumor-bearing hamsters drinking deionized water and healthy hamsters drinking deionized water.
Outcomes and reported result
Tumor appearance and size, mortality and survival, hematology and exploratory NES/DNES blood-serum spectral measures.
Mean tumor size on day 30 was 16.7±4.7 mm with hydrogen-rich water and 20.8±3.3 mm with deionized water. Mean survival was 46.4±8.1 versus 35.0±4.1 days, and the article reports a log-rank p<0.05. All controls died by day 40; all hydrogen-water animals died by day 57.
The complete free journal article was checked for allocation, preparation, concentration, schedule, growth, mortality, survival and laboratory outcomes.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Very small preclinical experiment; only five animals per tumor group remained for survival analysis after day-25 sampling. Water intake was not quantified, blinding was not reported and numerous endpoints were tested. A coauthor was affiliated with the device manufacturer Evodrop AG. The unusual NES/DNES serum analyses require independent validation.
Experimental myeloid tumor in hamsters only; it does not establish cancer prevention or treatment in people.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
DOI: 10.20471/LO.2023.51.02-03.13 · DOI: 10.20471/LO.2023.51.02-03.13
Free full article through Hrčak, Croatia's scientific-journal portal.
Libri Oncologici full article hosted by Hrčak; full-text extraction checked 8 August 2026.
2026-08-10